Mereo BioPharma Group, a United Kingdom-based clinical-stage biopharmaceutical firm, has agreed to merge with OncoMed Pharmaceuticals, an oncology-focused clinical stage biopharmaceutical business, it was reported yesterday.
The deal has been unanimously approved by the board of directors of each company. Subject to potential adjustment as described below, based upon an OncoMed net cash balance of USD38m at completion, current Mereo shareholders are expected to own around 75% of the issued share capital of the Enlarged Group, while current OncoMed shareholders are expected to own approximately 25% of the issued share capital of the Enlarged Group (through their holding of ADRs). In addition, OncoMed shareholders will receive CVRs representing the right to receive future conditional cash payments and additional ADRs based on the achievement of certain milestones relating to OncoMed assets.
Based on the terms of an agreement and plan of merger and reorganisation, unanimously approved by each party's board of directors, each share of OncoMed issued and held immediately prior to the deal becoming effective will be converted into the right to receive, Mereo ADRs pursuant to an exchange ratio that has been agreed, and one CVR representing the contingent right to receive certain cash payments and Mereo ADRs upon the achievement of certain milestones relating to the drugs etigilimab and navicixizumab.
TuHURA Biosciences acquires Kineta
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Mabwell and Qilu Pharmaceutical enter licence agreement for Albipagrastim alfa for Injection
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Biovica secures European patent for biomarker use in immuno-oncology
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Aiforia Technologies launches CE-IVD marked AI solution for breast cancer diagnostics
Stockholders approve proposed merger of TuHURA Biosciences and Kineta
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma